[Combined immunosuppression of FK506 and RS-61443 in rat limb allotransplantation]. 2003

Hao Kang, and Guang-xiang Hong, and Fa-bin Wang, and Zhen-bing Chen, and Qi-shun Huang, and Yu-xiong Weng
Department of Hand Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei, P.R. China 430022.

OBJECTIVE To study the immunosuppressive effect of combined therapy with FK506 and RS-61443 in rat limb allotransplantation. METHODS A total of 101 male SD rats were randomly divided into seven groups and used as recipients, and 101 Wistar rats were used as donors. All SD rats were performed limb allotransplantation without using immunosuppressants in control group. In experimental groups (Groups 1-6), the recipients were immunosuppressed with various dosages of FK506, RS-61443 or FK506 + RS61443, after transplantation for 5 weeks. To evaluate the results, we observed circulation of the transplanted limb, the mean rejection time, the histologic grading of skin rejection of limb grafts and the survival time of limb grafts. RESULTS The control group showed rejection signs (edema and erythema of the skin) after a mean time of 3.36 +/- 1.15 days, and the mean survival time of the allografts was only 7.00 +/- 0.78 days. In the groups only using FK506 or RS-61443, the survival time were prolonged to varying degrees, but rejection occurred even in the period of using drug. As dosage increased, the rejection could not be prevented and the damage to liver and kidney could be induced. In the group using FK506 in combination with RS-61443, only skin and muscle of limb allografts showed slight rejection sign, function of liver and kidney was not obviously affected, the mean survival time of limb allografts was prolonged to 58.76 +/- 6.81 days. CONCLUSIONS A combination of FK506 and RS-61443 is a more potent immunosuppressive agent than FK506 oro RS-61443 in preventing the rejection of limb allografts, and it can obviously prolong the survival time of limb allografts.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005121 Extremities The farthest or outermost projections of the body, such as the HAND and FOOT. Limbs,Extremity,Limb
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014183 Transplantation, Heterologous Transplantation between animals of different species. Xenotransplantation,Heterograft Transplantation,Heterografting,Heterologous Transplantation,Xenograft Transplantation,Xenografting,Transplantation, Heterograft,Transplantation, Xenograft
D016559 Tacrolimus A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro. Anhydrous Tacrolimus,FK-506,FK506,FR-900506,Prograf,Prograft,Tacrolimus Anhydrous,Anhydrous, Tacrolimus,FK 506,FR 900506,FR900506,Tacrolimus, Anhydrous

Related Publications

Hao Kang, and Guang-xiang Hong, and Fa-bin Wang, and Zhen-bing Chen, and Qi-shun Huang, and Yu-xiong Weng
February 1994, Transplantation,
Hao Kang, and Guang-xiang Hong, and Fa-bin Wang, and Zhen-bing Chen, and Qi-shun Huang, and Yu-xiong Weng
June 1997, Journal of hand surgery (Edinburgh, Scotland),
Hao Kang, and Guang-xiang Hong, and Fa-bin Wang, and Zhen-bing Chen, and Qi-shun Huang, and Yu-xiong Weng
April 1993, Transplantation proceedings,
Hao Kang, and Guang-xiang Hong, and Fa-bin Wang, and Zhen-bing Chen, and Qi-shun Huang, and Yu-xiong Weng
February 1996, Transplantation,
Hao Kang, and Guang-xiang Hong, and Fa-bin Wang, and Zhen-bing Chen, and Qi-shun Huang, and Yu-xiong Weng
May 1999, The Journal of hand surgery,
Hao Kang, and Guang-xiang Hong, and Fa-bin Wang, and Zhen-bing Chen, and Qi-shun Huang, and Yu-xiong Weng
December 1994, Muscle & nerve,
Hao Kang, and Guang-xiang Hong, and Fa-bin Wang, and Zhen-bing Chen, and Qi-shun Huang, and Yu-xiong Weng
June 2020, Journal of the Korean Association of Oral and Maxillofacial Surgeons,
Hao Kang, and Guang-xiang Hong, and Fa-bin Wang, and Zhen-bing Chen, and Qi-shun Huang, and Yu-xiong Weng
April 1998, Journal of reconstructive microsurgery,
Hao Kang, and Guang-xiang Hong, and Fa-bin Wang, and Zhen-bing Chen, and Qi-shun Huang, and Yu-xiong Weng
April 1991, Transplantation proceedings,
Hao Kang, and Guang-xiang Hong, and Fa-bin Wang, and Zhen-bing Chen, and Qi-shun Huang, and Yu-xiong Weng
December 1994, Transplantation proceedings,
Copied contents to your clipboard!